Drug Profile

IRX 5010

Alternative Names: IRX-5010

Latest Information Update: 17 Dec 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Io Therapeutics
Class Antineoplastics; Small molecules
Mechanism of Action Retinoic acid receptor gamma agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Breast cancer

Most Recent Events

12 Dec 2024 Pharmacodynamics data from a preclinical study in Breast cancer released by Io Therapeutics
12 Dec 2024 Io Therapeutics plans a clinical trial for Triple negative breast cancer
10 Dec 2024 Pharmacodynamics data from a preclinical study in Breast cancer presented at the 47th Annual San Antonio Breast Cancer Symposium .

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com